Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment‐related mortality is a research paper published in American Journal of Hematology (2020). On theSindex it has a DataRank of 0. It has been cited 103 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Institutes of Health
Grant: CCSG
National Institutes of Health
Grant: R01CA235622
National Cancer Institute
Grant: CA016672
NCI NIH HHS
Grant: P30 CA016672
National Institutes of Health
Grant: 5R01CA235622-02
Targeting apoptosis in high-risk AML and MDS with BCL-2 inhibitor Venetoclax and optimized 10-day Decitabine regimen
FWCI
6.52
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 1 of The predictive value of BTG1 for the response of newly diagnosed acute myeloid leukemia to decitabine
Additional file 1 of The predictive value of BTG1 for the response of newly diagnosed acute myeloid leukemia to decitabine